Dublin, Feb. 18, 2021 (GLOBE NEWSWIRE) -- The "Immunoprotein Diagnostic Testing Market by Technology, Type and Application: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
The global immunoprotein diagnostic testing market was valued at $10,136.40 million in 2019 and is projected to reach $18,387.19 million by 2027, registering a CAGR of 6.6% from 2020 to 2027. Immunoprotein is an immunologically active protein, which provides immunity against pathogenic organisms or substances. These proteins form the integrated body system of tissues, organs, cells, or cell products that neutralize antigens. They enable the diagnosis of various diseases, such as cardiovascular, oncology, infectious diseases, and others, as they display an abnormal increase in their concentration when in a diseased state.
The growth of the global immunoprotein diagnostic testing market is propelled by increase in incidence & prevalence of infectious and chronic diseases, rise in geriatric population, and growth in demand for early diagnostic services. In addition, technological advancements in immunodiagnostic instruments and introduction of novel automated systems are all set to augment the growth of immunoprotein diagnostic testing market during the forecast period. On the contrary, complex regulatory framework for immunoprotein diagnostic testing limits the growth of the market. Conversely, ongoing development in condition-specific assays & tests and the need for early diagnosis in the emerging economies across the world provide lucrative opportunities for the market growth.
The immunoprotein diagnostic testing market is segmented on the basis of type, application, technology, and region. Based on technology, the immunoprotein diagnostic testing market is classified into radioimmunoassay, immunoturbidity assay, immunoprotein electrophoresis, enzyme-linked immunosorbent assay, and others. Under the enzyme-linked immunosorbent assay, the market is further divided into chemiluminescence immunoassay, fluorescence immunoassay, and colorimetric immunoassay. Based on type, the market is categorized into C-reactive protein diagnostic test, complement system protein diagnostic test, pre-albumin diagnostic test, haptoglobin diagnostic test, immunoglobulin diagnostic test, free light chain diagnostic test, and others. Applications of immunoprotein diagnostic testing covered in the study include autoimmune disease testing, infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Stakeholders
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2027, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the global immunoprotein diagnostic testing market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Key Topics Covered:
Chapter 1: Introduction
1.1. Report Description
1.1. Key Benefits for Stakeholders
1.2. Key Market Segments
1.3. Research Methodology
1.3.1. Secondary Research
1.3.2. Primary Research
1.3.3. Analyst Tools & Models
Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Increasing Incidence of Chronic and Infectious Diseases
3.4.1.2. Technological Advancements
3.4.2. Restraint
3.4.2.1. Stringent Regulations
3.4.3. Opportunities
3.4.3.1. Lucrative Opportunities from Emerging Economies
3.4.3.2. Development of Condition-Specific Assays and Tests
3.5. Covid-19 Impact Analysis on Market
Chapter 4: Immunoprotein Diagnostic Testing Market, by Technology
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Radioimmunoassay (Ria)
4.2.1. Key Market Trends and Opportunities
4.2.2. Market Size and Forecast
4.2.3. Market Analysis, by Country
4.3. Immunoturbidity Assay
4.3.1. Key Market Trends and Opportunities
4.3.2. Market Size and Forecast
4.3.3. Market Analysis, by Country
4.4. Immunoprotein Electrophoresis
4.4.1. Key Market Trends and Opportunities
4.4.2. Market Size and Forecast
4.4.3. Market Analysis, by Country
4.5. Enzyme Based Immunoassay
4.5.1. Key Market Trends and Opportunities
4.5.2. Market Size and Forecast
4.5.3. Market Analysis, by Country
4.5.3.1. Chemiluminescence Immunoassay (Clia)
4.5.3.2. Immunofluorescence Assay
4.5.3.3. Colorimetric Immunoassay (Ci)
4.6. Others
4.6.1. Key Market Trends and Opportunities
4.6.2. Market Size and Forecast
4.6.3. Market Analysis, by Country
Chapter 5: Immunoprotein Diagnostic Testing Market, by Type
5.1. Overview
5.1.1. Market Size and Forecast, by Type
5.2. C-Reactive Protein Diagnostic Tests
5.2.1. Market Size and Forecast
5.2.2. Market Analysis, by Country
5.3. Complement System Protein Diagnostic Tests
5.3.1. Market Size and Forecast
5.3.2. Market Analysis, by Country
5.4. Pre-Albumin Diagnostic Tests
5.4.1. Market Size and Forecast
5.4.2. Market Analysis, by Country
5.5. Haptoglobin Diagnostic Tests
5.5.1. Market Size and Forecast
5.5.2. Market Analysis, by Country
5.6. Immunoglobulin Diagnostic Tests
5.6.1. Market Size and Forecast
5.6.2. Market Analysis, by Country
5.7. Free Light Chain Diagnostic Tests
5.7.1. Market Size and Forecast
5.7.2. Market Analysis, by Country
5.8. Others
5.8.1. Market Size and Forecast
5.8.2. Market Analysis, by Country
Chapter 6: Immmunoprotein Diagnostic Testing Market, by Application
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Autoimmune Testing
6.2.1. Market Size and Forecast
6.2.2. Market Analysis, by Country
6.3. Infectious Disease Testing
6.3.1. Market Size and Forecast
6.3.2. Market Analysis, by Country
6.4. Allergy Testing
6.4.1. Market Size and Forecast
6.4.2. Market Analysis, by Country
6.5. Endocrine Testing
6.5.1. Market Size and Forecast
6.5.2. Market Analysis, by Country
6.6. Oncology Testing
6.6.1. Market Size and Forecast
6.6.2. Market Analysis, by Country
6.7. Toxicology Testing
6.7.1. Market Size and Forecast
6.7.2. Market Analysis, by Country
6.8. Others
6.8.1. Market Size and Forecast
6.8.2. Market Analysis, by Country
Chapter 7: Immunoprotein Diagnostic Testing Market, by Region
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia-Pacific
7.5. LAMEA
Chapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves and Developments
8.2. Abcam plc.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.3. Bio-Rad Laboratories, Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.6. Key Strategic Moves and Developments
8.4. Danaher Corporation
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.5. Diasorin S. P. A
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves and Developments
8.6. Enzo Biochem, Inc.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. F. Hoffmann-La Roche AG (Roche Diagnostics)
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves and Developments
8.8. Ortho Clinical Diagnostics
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Key Strategic Moves and Developments
8.9. Siemens AG
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Thermo Fisher Scientific Inc.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
For more information about this report visit https://www.researchandmarkets.com/r/amjfr8